Image-Based Three-Dimensional Radiation Dosimetry for Ac-225-MTI-201
Targeted alpha-particle therapy (TAT), such as Ac-225-MTI-201, can kill cells within tumors while also targeting cancer cells throughout the body. TAT works by bringing a radioactive isotope, in this case actinium 225, to areas that contain cancer cells. Our TAT is a novel radiotherapy with excellent properties for the treatment of metastatic uveal melanoma. However, two main challenges face TAT application in clinic – accurately determining the dose that is delivered (dosimetry) and visualizing where the TAT goes within the body. This project proposes to develop a novel three-dimensional internal radiation dosimetry (3D-RD) method for accurate and personalized TAT for metastatic uveal melanoma. We will also develop Cu-64-MTI-201 as a companion imaging agent to have similar properties as Ac-225-MTI-201 but is readily visualized with positron emission tomography (PET). These tools should enable and expedite the clinical translation of our TAT in a way that is accurate and tailored to individual patients.
